Back to Search
LORI FEIN, M.D.
M.D.
Specialist
NPI: 1962465583Individual
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
ME0043928(FL)
Research & Publications (9)
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
PMID 18316794·J Clin Oncol·2008
3-trial
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
PMID 17968020·J Clin Oncol·2007
3-trial
Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
PMID 17588704·Lung Cancer·2007
3-trial
Gallbladder cancer: surgical results after cholecystectomy in 25 patients with lamina propria invasion and 26 patients with muscular layer invasion.
PMID 17139432·J Hepatobiliary Pancreat Surg·2006
8-other
Prevalence of Borrelia burgdorferi, Bartonella spp., Babesia microti, and Anaplasma phagocytophila in Ixodes scapularis ticks collected in Northern New Jersey.
PMID 15184475·J Clin Microbiol·2004
7-preclinical
Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.
PMID 11510033·Semin Oncol·2001
3-trial
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
PMID 11970744·Clin Breast Cancer·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 8701 SW 128TH ST
MIAMI, FL 33176 - Phone
- (305) 234-1700
Quick Facts
- NPI
- 1962465583
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 9
Are you this provider?
Claim Your Profile